(2S)-2-({[(1S)-1-(1,3-benzodioxol-5-yl)-3-hydroxypropyl]carbamoyl}amino)hexylbis(2-thienylmethyl)carbamate | 1378533-10-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: (2S)-2-({[(1S)-1-(1,3-benzodioxol-5-yl)-3-hydroxypropyl]carbamoyl}amino)hexylbis(2-thienylmethyl)carbamate
• 英文别名: (2S)-2-({[(1S)-1-(1,3-benzodioxol-5-yl)-3-hydroxypropyl]carbamoyl}amino)hexyl bis(2-thienylmethyl)carbamate；[(2S)-2-[[(1S)-1-(1,3-benzodioxol-5-yl)-3-hydroxypropyl]carbamoylamino]hexyl] N,N-bis(thiophen-2-ylmethyl)carbamate
• CAS: 1378533-10-8
• 化学式: C₂₈H₃₅N₃O₆S₂
• 分子量: 573.734
• InChiKey: IMHJHTBYDGFTJW-URXFXBBRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  39
• 可旋转键数：
  15
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  166
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  3,4-methylenedioxy-trans-cinnamic acid 在 palladium on activated charcoal 锂硼氢 、 正丁基锂 、 氢气 、 对甲苯磺酸 、 溶剂黄146 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 正己烷 、 二氯甲烷 、 水 、 1,2-二氯乙烷 为溶剂， 反应 54.5h， 生成 (2S)-2-({[(1S)-1-(1,3-benzodioxol-5-yl)-3-hydroxypropyl]carbamoyl}amino)hexylbis(2-thienylmethyl)carbamate
  参考文献：
  名称：

  [EN] AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS
  [FR] AGONISTES AMÉLIORANT LA LIAISON DE CELLULES EXPRIMANT DES INTÉGRINES À DES RÉCEPTEURS D'INTÉGRINES

  摘要：

  公开号：

  WO2012068251A3

文献信息

• AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS
  申请人：Biediger Ronald J.

  公开号：US20130236434A1

  公开（公告）日：2013-09-12

  A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.

  一种增强细胞与整合素结合配体的结合的方法包括在体外用整合素激动剂处理表达整合素的细胞，其中整合素选自α4β1、α5β1、α4β7、αvβ3和αLβ2群，然后将处理后的细胞与整合素结合配体接触；具有一般式I的整合素激动剂化合物；使用这种激动剂治疗表达整合素的细胞以增强结合的方法；以及包括将激动剂处理的细胞或激动剂化合物给哺乳动物的治疗方法。
• AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS
  申请人：TEXAS HEART INSTITUTE

  公开号：US20150368234A1

  公开（公告）日：2015-12-24

  A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.

  一种增强细胞与整合素结合配体结合的方法包括在体外用整合素激动剂处理表达整合素的细胞，其中整合素被选择自α4β1、α5β1、α4β7、αvβ3和αLβ2组成的群体中的一种，并将处理后的细胞与整合素结合配体接触；具有一般式I的整合素激动剂化合物；用这样的激动剂处理表达整合素的细胞以增强结合的方法；以及包括向哺乳动物施用经激动剂处理的细胞或激动剂化合物的治疗方法。
• Agonists that enhance binding of integrin-expressing cells to integrin receptors
  申请人：Texas Heart Institute

  公开号：EP2881392A1

  公开（公告）日：2015-06-10

  A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.

  一种增强细胞与整合素结合配体结合的方法，包括在体外用整合素的激动剂处理表达整合素的细胞，其中整合素选自由α4β1、α5β1、α4β7、αvβ3和αLβ2组成的组，并使处理过的细胞与整合素结合配体接触；具有通式Ⅰ的整合素激动剂化合物；用这种激动剂处理整合素表达细胞以增强结合的方法；以及治疗方法，包括给哺乳动物施用激动剂处理过的细胞或激动剂化合物。
• Agonists that enhanced binding of integrin-expressing cells to integrin receptors
  申请人：TEXAS HEART INSTITUTE

  公开号：US10035784B2

  公开（公告）日：2018-07-31

  A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.

  一种增强细胞与整合素结合配体结合的方法，包括在体外用整合素的激动剂处理表达整合素的细胞，其中整合素选自由α4β1、α5β1、α4β7、αvβ3和αLβ2组成的组，并使处理过的细胞与整合素结合配体接触；具有通式Ⅰ的整合素激动剂化合物；用这种激动剂处理整合素表达细胞以增强结合的方法；以及治疗方法，包括给哺乳动物施用激动剂处理过的细胞或激动剂化合物。
• Compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants
  申请人：7 Hills Interests LLC

  公开号：US10342866B2

  公开（公告）日：2019-07-09

  Small molecule integrin ligand mimetics facilitate integrin-ligand interactions, which may be used to prepare vaccines, adoptive cell therapies, immunotherapies for cancer, and a variety of other conditions. As integrin mediated cell-cell interactions are critical to antigen presentation and effector cell killing, increasing the efficiency of integrin receptor-ligand interactions will stabilize the immune synapse and improve effector functions. Compositions and methods including the mimetics enhance: (1) the priming of vaccines (including, but not limited to, cancer vaccines); (2) cytolytic activity of adoptive cell therapies (including, but not limited to γδT-cells, CTLs, NK, iNKT); (3) immunotherapies (including, but not limited to, negative checkpoint blockage strategies such as anti-CTLA-4 and anti-PD-1); and (4) biologic therapies (including, but not limited, to trastuzumab and rituxamab), whereby the mechanism-of-action includes antibody dependent cellular cytotoxicity (ADCC).

  小分子整合素配体模拟物能促进整合素与配体之间的相互作用，可用于制备疫苗、采用性细胞疗法、癌症免疫疗法以及其他多种治疗方法。由于整合素介导的细胞-细胞相互作用对于抗原递呈和效应细胞杀伤至关重要，因此提高整合素受体-配体相互作用的效率将稳定免疫突触并改善效应功能。包括模拟物在内的组合物和方法可提高(1) 疫苗（包括但不限于癌症疫苗）的启动；(2) 接种细胞疗法（包括但不限于γδT 细胞、CTL、NK、iNKT）的细胞溶解活性；(3) 免疫疗法（包括但不限于阴性检查点阻断策略，如抗 CTLA-4 和抗 PD-1）；以及 (4) 生物疗法（包括但不限于曲妥珠单抗和利妥昔单抗），其作用机制包括抗体依赖性细胞毒性（ADCC）。